Might only be a subtle change - but I've noticed today that the Pipeline on Bard1's website seems to have been updated since the Nov 20 presentation.
In Nov 20 the presentation showed the pipeline as follows:
But you will note that now on their website they have quietly included Pancreatic Cancer on the SubB2M future pipeline (see below).
So from here my guess on the SubB2M process is we will hear on prostate cancer first, then sometime in the future they will be trying to validate the test to Pancreatic Cancer as well.
Also interesting to note that they have Breast and Ovarian Cancer usage as monitoring based tests (not used as a screening test (yet)) and the Prostate and Pancreatic Tests they are aiming to be used as screening tests for early detection.
Be patient everyone - potentially exciting times ahead - a stock never goes up in a straight line every day!
Cheers
Hevlet
